As scientists continue to expand the utility of biomarkers in basic and applied life science research, advances in immunoassay technologies further empower these efforts by improving the way key markers of health and disease are identified, characterized, and measured in biological samples. In particular, recent advances of ultrasensitive assay platforms strive to enable researchers to better understand the importance and application of both novel and existing biomarkers by detecting them at levels never before possible. In doing so, scientists are able to more confidently draw meaningful conclusions regarding molecules important in early disease onset and characterize the modulation of efficacy and safety biomarkers in clinical trials, potentiating future advances in the development of therapeutics.
MilliporeSigma is excited to invite you to our upcoming virtual symposium on the power of Single Molecule Counting (SMC™) ultrasensitive immunoassay technology on March 31, 2021. Whether you are already working on the cutting edge of biomarker research, or are seeking to learn how immunoassays can enable your next scientific breakthrough, join our symposium to:
Biology Technical Marketing, Merck
Principal Scientist, Aptevo Therapeutics
Scientific Project Manager, Vaccine Immunology Program (VIP), Vaccine Research Center (VRC), NIAID, NIH
Chief Scientific Officer, DESTINA